4-aminopyridine has been researched along with Disease Models, Animal in 167 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hence, thalidomide (100, 200 and 400 mg/kg) was herein administered to mice to evaluate possible protection against seizures induced by the systemic administration of neurotoxins: 10 mg/kg of 4-aminopyridine (4-AP), 90 mg/kg of pentylenetetrazol (PTZ), or 380 mg/kg of pilocarpine." | 7.88 | Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice. ( Campos-Rodriguez, C; Islas-Espinoza, AM; San Juan, ER, 2018) |
| " Seizures were induced with one of Pentelyntetrazole (PTZ), 4-Aminopyridine (AP) and Strychnine (STR)." | 7.85 | Antiseizure Effects of Ketogenic Diet on Seizures Induced with Pentylenetetrazole, 4-Aminopyridine and Strychnine in Wistar Rats. ( Desalu, OO; Kolo, PM; Olarinoye, JK; Olatunji, LA; Sanya, EO; Soladoye, AO, 2017) |
| "), its effects on seizures, EEG epileptiform activity and EEG amplitude increases induced by two convulsive agents were evaluated and compared with the effects of carbamazepine." | 7.78 | The antidepressant sertraline prevents the behavioral and EEG changes induced in two animal models of seizures. ( Aldana, BI; Gómez, CD; Nekrassov, V; Sitges, M, 2012) |
| "Epileptiform discharges recorded in the 4-aminopyridine (4-AP) in vitro epilepsy model are mediated by glutamatergic and GABAergic signaling." | 7.77 | The 4-aminopyridine in vitro epilepsy model analyzed with a perforated multi-electrode array. ( Avoli, M; Dzakpasu, R; Gonzalez-Sulser, A; Motamedi, GK; Vicini, S; Wang, J, 2011) |
| "2 channel and of its major modulator, voltage-dependent potassium channel-interacting protein (KChIP1), is altered following lithium-pilocarpine induced status epilepticus (SE) and the chronic-epilepsy phase in the rat model." | 7.74 | Altered expression of voltage-gated potassium channel 4.2 and voltage-gated potassium channel 4-interacting protein, and changes in intracellular calcium levels following lithium-pilocarpine-induced status epilepticus. ( Cong, WD; Deng, WY; Liao, WP; Long, YS; Luo, AH; Su, T; Sun, WW, 2008) |
| "To observe and compare the effect of taurine on contractions of aortic rings isolated from normal (NC) and insulin resistance (IR) Sprague-Dawley rats, and to explore its underlying mechanism(s)." | 7.74 | Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed. ( Li, J; Liang, Y; Niu, L; Wu, D; Xue, W; Zhang, M, 2008) |
| "We investigated the effects of valproate (VPA) on an in vivo model of status epilepticus (SE) induced by intrahippocampal application of 4-aminopyridine (4-AP)." | 7.72 | Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. ( Martín, ED; Pozo, MA, 2003) |
| " Anticonvulsant effects were evaluated against seizures induced by 14 mg kg(-1) of 4-aminopyridine (4-AP) and by 110 mg kg(-1) of pentylenetetrazole (PTZ), and neurotoxicity by the rotarod test." | 7.72 | Is the interaction between felbamate and valproate against seizures induced by 4-aminopyridine and pentylenetetrazole in mice beneficial? ( Amat, G; Armijo, JA; Cuadrado, A, 2003) |
| "Seizures were prevented in 50% and 75% of the animals by chronic CBZ and VPC, respectively." | 5.35 | Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine. ( Nekrassov, V; Sitges, M, 2008) |
| "GYKI 52466 was effective in prolonging the latency to generalised seizures and reduction of seizure mortality." | 5.35 | Blockade of AMPA-receptors attenuates 4-aminopyridine seizures, decreases the activation of inhibitory neurons but is ineffective against seizure-related astrocytic swelling. ( Krisztin-Péva, B; Mihály, A; Weiczner, R, 2008) |
| " In this study we used the pilocarpine-induced status epilepticus model of TLE (i." | 3.91 | Altered A-type potassium channel function in the nucleus tractus solitarii in acquired temporal lobe epilepsy. ( Derera, ID; Smith, BN; Smith, KC, 2019) |
| "To explore the role of cGKII in epilepsy, we investigated the expression of cGKII in patients with temporal lobe epilepsy (TLE) and in a pilocarpine-induced rat model and then performed behavioral, histological, and electrophysiological analyses by applying either a cGKII agonist or inhibitor in the hippocampus of the animal model." | 3.88 | Inhibition of Cgkii Suppresses Seizure Activity and Hippocampal Excitation by Regulating the Postsynaptic Delivery of Glua1. ( Gu, J; Lin, P; Lin, Z; Lu, S; Luo, J; Ma, Y; Tian, X; Wang, W; Wang, X; Xiao, F; Xiong, Y; Xu, D; Yang, Q; Yang, Y; Zhang, Y, 2018) |
| " Hence, thalidomide (100, 200 and 400 mg/kg) was herein administered to mice to evaluate possible protection against seizures induced by the systemic administration of neurotoxins: 10 mg/kg of 4-aminopyridine (4-AP), 90 mg/kg of pentylenetetrazol (PTZ), or 380 mg/kg of pilocarpine." | 3.88 | Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice. ( Campos-Rodriguez, C; Islas-Espinoza, AM; San Juan, ER, 2018) |
| " Seizures were induced with one of Pentelyntetrazole (PTZ), 4-Aminopyridine (AP) and Strychnine (STR)." | 3.85 | Antiseizure Effects of Ketogenic Diet on Seizures Induced with Pentylenetetrazole, 4-Aminopyridine and Strychnine in Wistar Rats. ( Desalu, OO; Kolo, PM; Olarinoye, JK; Olatunji, LA; Sanya, EO; Soladoye, AO, 2017) |
| " Approximately 3-4 wk later recurrent electrographic seizures were evoked by local application of the chemoconvulsant 4-aminopyridine (4-AP); the ECoG and unit activity were monitored with extracellular silicone electrodes; and PV interneurons were activated optogenetically during the ictal and interictal phases." | 3.83 | The antiepileptic and ictogenic effects of optogenetic neurostimulation of PV-expressing interneurons. ( Assaf, F; Schiller, Y, 2016) |
| " Ripples (80-200 Hz) and fast ripples (250-500 Hz) have been linked to each pattern, with ripples predominating during LVF seizures and fast ripples predominating during HYP seizures in the rat pilocarpine model." | 3.81 | Distinct EEG seizure patterns reflect different seizure generation mechanisms. ( Avoli, M; Gotman, J; Lévesque, M; Salami, P, 2015) |
| "), its effects on seizures, EEG epileptiform activity and EEG amplitude increases induced by two convulsive agents were evaluated and compared with the effects of carbamazepine." | 3.78 | The antidepressant sertraline prevents the behavioral and EEG changes induced in two animal models of seizures. ( Aldana, BI; Gómez, CD; Nekrassov, V; Sitges, M, 2012) |
| " Using a conditional transgenic mouse model, selective ablation of adult neural stem and progenitor cells in the subventricular zone induced a dramatic increase in morbidity and mortality of central nervous system disorders characterized by excitotoxicity-induced cell death accompanied by reactive inflammation, such as 4-aminopyridine-induced epilepsy and ischaemic stroke." | 3.78 | Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity. ( Bacigaluppi, M; Bari, M; Brambilla, E; Butti, E; Cambiaghi, M; Cebrian Silla, A; Centonze, D; Comi, G; D'Adamo, P; De Ceglia, R; De Chiara, V; Garcia-Verdugo, JM; Leocani, L; Maccarrone, M; Martino, G; Musella, A; Muzio, L; Quattrini, A; Rossi, S; Teneud, L, 2012) |
| "Previous theories assumed that the beneficial effect of the potassium channel blocker 4-aminopyridine (4-AP) for patients suffering from downbeat nystagmus (DBN) or episodic ataxia type 2 (EA2) is due to an increase of excitability of cerebellar Purkinje cells (PC)." | 3.77 | The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus. ( Glasauer, S; Rössert, C; Strupp, M, 2011) |
| "Epileptiform discharges recorded in the 4-aminopyridine (4-AP) in vitro epilepsy model are mediated by glutamatergic and GABAergic signaling." | 3.77 | The 4-aminopyridine in vitro epilepsy model analyzed with a perforated multi-electrode array. ( Avoli, M; Dzakpasu, R; Gonzalez-Sulser, A; Motamedi, GK; Vicini, S; Wang, J, 2011) |
| "This study investigated the in vitro antioxidant activity of (E)-2-benzylidene-4-phenyl-1,3-diselenole (BPD), the anticonvulsant effect of BPD on seizures induced by pilocarpine (PC), pentylenetetrazole (PTZ) and 4-aminopyridine (4-AMP) and the mechanism involved." | 3.76 | Anticonvulsant effect of (E)-2-benzylidene-4-phenyl-1,3-diselenole in a pilocarpine model in mice. ( Bortolatto, CF; Jesse, CR; Nogueira, CW; Roman, SS; Wilhelm, EA, 2010) |
| "This study was designed to elucidate the contribution of adenosine A(2A) and A(2B) receptors to coronary reactive hyperemia and downstream K(+) channels involved." | 3.76 | Contribution of adenosine A(2A) and A(2B) receptors to ischemic coronary dilation: role of K(V) and K(ATP) channels. ( Berwick, ZC; Dick, GM; Lynch, B; Payne, GA; Sturek, M; Tune, JD, 2010) |
| " Consistent with these observations, acetoacetate reduced quantal size at hippocampal synapses and suppresses glutamate release and seizures evoked with 4-aminopyridine in the brain." | 3.76 | Metabolic control of vesicular glutamate transport and release. ( Edwards, RH; Gray, JA; Hara, C; Inoue, T; Juge, N; Miyaji, T; Moriyama, Y; Nicoll, RA; Omote, H; Uneyama, H, 2010) |
| " CBD (1, 10, and 100 mg/kg) effects were also examined in vivo using the pentylenetetrazole model of generalized seizures." | 3.76 | Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. ( Bevan, SA; Hill, AJ; Jones, NA; Smith, I; Stephens, GJ; Whalley, BJ; Williams, CM, 2010) |
| "2 channel and of its major modulator, voltage-dependent potassium channel-interacting protein (KChIP1), is altered following lithium-pilocarpine induced status epilepticus (SE) and the chronic-epilepsy phase in the rat model." | 3.74 | Altered expression of voltage-gated potassium channel 4.2 and voltage-gated potassium channel 4-interacting protein, and changes in intracellular calcium levels following lithium-pilocarpine-induced status epilepticus. ( Cong, WD; Deng, WY; Liao, WP; Long, YS; Luo, AH; Su, T; Sun, WW, 2008) |
| "To observe and compare the effect of taurine on contractions of aortic rings isolated from normal (NC) and insulin resistance (IR) Sprague-Dawley rats, and to explore its underlying mechanism(s)." | 3.74 | Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed. ( Li, J; Liang, Y; Niu, L; Wu, D; Xue, W; Zhang, M, 2008) |
| "We investigated the potential of 4-AP (50-100 microM) to induce seizure-like events (SLEs) in combined entorhinal cortex-hippocampal slices from Sprague Dawley rats which developed spontaneous limbic seizures following kainic acid induced status epilepticus." | 3.74 | Reduced ictogenic potential of 4-aminopyridine in the perirhinal and entorhinal cortex of kainate-treated chronic epileptic rats. ( Derst, C; Gruber, C; Heinemann, U; Tolner, EA; Veh, RW; Zahn, RK, 2008) |
| "Excessive release of L-glutamic acid (glu) has been associated with seizures and epilepsy." | 3.74 | Simultaneous glutamate and EEG activity measurements during seizures in rat hippocampal region with the use of an electrochemical biosensor. ( López-Pérez, SJ; Medina-Ceja, L; Morales-Villagrán, A, 2008) |
| "The functional significance of gap-junction (GJ) channels in seizure susceptibility and induction and maintenance of seizures in the developing rat brain was investigated on the 4-aminopyridine (4-AP) in vivo epilepsy model." | 3.73 | The functional significance of gap junction channels in the epileptogenicity and seizure susceptibility of juvenile rats. ( Gajda, Z; Gyengési, E; Hermesz, E; Szente, M; Szupera, Z, 2006) |
| "The possible role of gap junctions in the manifestation and control of the duration of seizures was tested on the 4-aminopyridine-induced epilepsy model in rats in vivo, by using electrophysiologic, pharmacologic, and molecular biologic techniques." | 3.72 | Involvement of gap junctions in the manifestation and control of the duration of seizures in rats in vivo. ( Ali, KS; Gajda, Z; Gyengési, E; Hermesz, E; Szente, M, 2003) |
| " Anticonvulsant effects were evaluated against seizures induced by 14 mg kg(-1) of 4-aminopyridine (4-AP) and by 110 mg kg(-1) of pentylenetetrazole (PTZ), and neurotoxicity by the rotarod test." | 3.72 | Is the interaction between felbamate and valproate against seizures induced by 4-aminopyridine and pentylenetetrazole in mice beneficial? ( Amat, G; Armijo, JA; Cuadrado, A, 2003) |
| "We investigated the effects of valproate (VPA) on an in vivo model of status epilepticus (SE) induced by intrahippocampal application of 4-aminopyridine (4-AP)." | 3.72 | Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. ( Martín, ED; Pozo, MA, 2003) |
| " Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia." | 3.69 | Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats. ( Keyler, DE; Pentel, PR; Wananukul, W, 1996) |
| " GYKI 52466 was also protective against seizures and lethality induced by 4-aminopyridine, kainate and AMPA, but not by NMDA, whereas NBQX was ineffective in these chemoconvulsant tests." | 3.68 | Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. ( Donevan, SD; Rogawski, MA; Yamaguchi, S, 1993) |
| "Rats underwent permanent middle cerebral artery occlusion." | 2.78 | Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion. ( Barrile, DK; Blight, AR; Caggiano, AO; Davenport, MD; Finklestein, SP; Huang, Z; Iaci, JF; Parry, TJ; Ren, J; Wu, R, 2013) |
| "We find that the seizure focus elicits a rapid alteration in triggering, initiation, and propagation of burst suppression events." | 1.51 | Burst suppression uncovers rapid widespread alterations in network excitability caused by an acute seizure focus. ( Baird-Daniel, E; Daniel, A; Liou, JY; Ma, H; Schevon, CA; Schwartz, TH; Zhao, M, 2019) |
| "Rosmarinic acid (RA) is an ester of caffeic acid and 3,4-dihydroxyphenylactic acid that prevents cell damage caused by free radicals, acting as an antioxidant." | 1.51 | Rosmarinic acid improves oxidative stress parameters and mitochondrial respiratory chain activity following 4-aminopyridine and picrotoxin-induced seizure in mice. ( da Rosa, MS; Gonçalves, D; Leipnitz, G; Luft, JG; Morás, AM; Moura, DJ; Pereira, P; Pflüger, PF; Regner, GG; Steffens, L, 2019) |
| "Recent evidence shows that seizures propagate primarily through supragranular cortical layers." | 1.51 | In Vivo Femtosecond Laser Subsurface Cortical Microtransections Attenuate Acute Rat Focal Seizures. ( Baird-Daniel, E; Fetcho, R; Lieberman, S; Liu, L; Ma, H; Nagappan, S; Nguyen, J; Nishimura, N; Radwanski, RE; Schaffer, CB; Schwartz, TH; Zhao, M, 2019) |
| "Epilepsy is a group of neurological disorders which affects millions of people worldwide." | 1.51 | Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice. ( Kaszas, A; Malliaras, GG; Proctor, CM; Slezia, A; Williamson, A, 2019) |
| "Nitroxyl anion (HNO) has recently become an emerging candidate in vascular regulation." | 1.46 | Nitroxyl Anion Mediates Relaxation in Mesenteric Arteries from Angiotensin II Hypertensive Mice. ( Labazi, H; Tostes, RC; Webb, RC; Wynne, BM, 2017) |
| "Ischemia-reperfusion injury is the major complication of abdominal aortic surgery, and it mainly affects the lower extremities and remote organs." | 1.46 | Electrophysiological alterations in diaphragm muscle caused by abdominal ischemia-reperfusion. ( Burat, I; Dalkilic, N; Tuncer, S, 2017) |
| "Thus, reactive gliosis and a significant increase in the expression of caspase-9 were found in the aforementioned brain area." | 1.46 | Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats. ( de la Rosa, RF; Delgado, M; García-García, L; Pozo, MA; Shiha, AA, 2017) |
| "Anaphylactic shock is associated with severe hypotension." | 1.43 | 4-Aminopyridine, A Blocker of Voltage-Dependent K+ Channels, Restores Blood Pressure and Improves Survival in the Wistar Rat Model of Anaphylactic Shock. ( Aburawi, EH; Al-Hammadi, S; Alper, SL; Bellou, A; Bellou, L; Bellou, S; Dhanasekaran, S; Kazzam, E; Nemmar, A; Oulhaj, A; Shafiuallah, M; Yasin, J; Zerrouki, M, 2016) |
| "Status epilepticus (SE) is defined as a seizure lasting more than 5min or a period of recurrent seizures without recovery between them." | 1.43 | High frequency oscillations can pinpoint seizures progressing to status epilepticus. ( Avoli, M; Lévesque, M; Salami, P, 2016) |
| "Severity of 6-OHDA-induced Parkinsonism was assessed by conventional behavioural tests." | 1.43 | Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation. ( Alipour Heidari, M; Dargahi, T; Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Mahmudi, M; Piri, H, 2016) |
| " We further found that chronic administration of the FDA-approved drug 4-aminopyridine (4-AP), which targets potassium channels, alleviated motor coordination deficits and restored cerebellar Purkinje cell firing precision to wildtype (WT) levels in SCA6(84Q/84Q) mice both in acute slices and in vivo." | 1.43 | 4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6. ( Chang, HH; Cullen, KE; Jayabal, S; Watt, AJ, 2016) |
| "The baseline mean seizure frequencies were 5." | 1.42 | Rapid brief feedback intracerebral stimulation based on real-time desynchronization detection preceding seizures stops the generation of convulsive paroxysms. ( Genov, R; Kassiri, H; Perez Velazquez, JL; Salam, MT, 2015) |
| "IL-1R1 knockout or IL-1RA enhanced the seizure refractory phenomenon without influencing the baseline seizure threshold in intermittent MES model." | 1.42 | The Pro-inflammatory Cytokine Interleukin-1β is a Key Regulatory Factor for the Postictal Suppression in Mice. ( Chen, B; Chen, Z; Hu, WW; Shi, LY; Tang, YS; Tao, AF; Wang, Y; Wu, XH; Xu, CL; Xu, ZH; Zhang, J; Zhang, SH; Zhao, HW, 2015) |
| "Epilepsy is a chronic brain disease characterised by recurrent seizures." | 1.42 | Heterogeneous effects of antiepileptic drugs in an in vitro epilepsy model--a functional multineuron calcium imaging study. ( Hasegawa, M; Hongo, Y; Ikegaya, Y; Ogawa, K; Sakaguchi, G; Takasu, K, 2015) |
| "Interictal spikes in models of focal seizures and epilepsies are sustained by the synchronous activation of glutamatergic and GABAergic networks." | 1.42 | Synchronous inhibitory potentials precede seizure-like events in acute models of focal limbic seizures. ( Breschi, GL; de Curtis, M; Gnatkovsky, V; Taverna, S; Uva, L, 2015) |
| "The long-term effects of DCS on seizures were not influenced by the depotentiation blocker FK-506." | 1.42 | Treatment with direct-current stimulation against cingulate seizure-like activity induced by 4-aminopyridine and bicuculline in an in vitro mouse model. ( Chang, WP; Lu, HC; Shyu, BC, 2015) |
| "A closed-loop seizure control system was then implemented based on optimal eTBS parameters." | 1.40 | Suppression of acute seizures by theta burst electrical stimulation of the hippocampal commissure using a closed-loop system. ( Chiang, CC; Ju, MS; Lin, CC; Siah, BH, 2014) |
| " Optimization of both binding mode and pharmacokinetic properties of these compounds led to potent inhibitors against experimental T." | 1.40 | 4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency. ( Calvet, CM; Cameron, MD; Choi, JY; Gut, J; Johnston, JB; Kellar, D; Khan, S; Lin, L; McKerrow, JH; Podust, LM; Roush, WR; Siqueira-Neto, JL; Vieira, DF, 2014) |
| "Hydrogen sulfide (H2 S) is a gas transmitter that may mediate cerebral ischemic injury." | 1.40 | Aggravation of seizure-like events by hydrogen sulfide: involvement of multiple targets that control neuronal excitability. ( Chen, JG; Guan, XL; He, JG; Hu, ZL; Luo, Y; Wang, F; Wu, PF; Xiao, W; Zhang, JT; Zhou, J, 2014) |
| "Seizures were induced by global hypoxia (5-7% O2 for 15 min) in rat pups on postnatal day 10." | 1.39 | Decreased A-currents in hippocampal dentate granule cells after seizure-inducing hypoxia in the immature rat. ( He, XH; Justice, JA; Peng, BW; Sanchez, RM, 2013) |
| "Cold allodynia, pain in response to cooling, occurs during or within hours of oxaliplatin infusion and is thought to arise from a direct effect of oxaliplatin on peripheral sensory neurons." | 1.39 | An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. ( Cabot, PJ; Deuis, JR; Lewis, RJ; Possani, LD; Romanovsky, AA; Vetter, I; Zimmermann, K, 2013) |
| "Cancer pain is one of the most severe types of chronic pain, and the most common cancer pain is bone cancer pain." | 1.38 | Targeting A-type K(+) channels in primary sensory neurons for bone cancer pain in a rat model. ( Duan, KZ; Mei, YA; Xu, Q; Zhang, XM; Zhang, YQ; Zhao, ZQ, 2012) |
| "While chronic pain is a main symptom in endometriosis, the underlying mechanisms and effective therapy remain elusive." | 1.38 | Ectopic uterine tissue as a chronic pain generator. ( Alvarez, P; Chen, X; Giudice, LC; Green, PG; Hendrich, J; Irwin, JC; Levine, JD, 2012) |
| "Cingulate seizure-like activities were modulated significantly by thalamic inputs." | 1.37 | Spatiotemporal organization and thalamic modulation of seizures in the mouse medial thalamic-anterior cingulate slice. ( Chang, WP; Lee, CM; Shyu, BC; Vogt, BA; Wu, JS, 2011) |
| "Because our seizure model is very severe, it is probable that this technique would have a robust effect in human focal epilepsy." | 1.36 | Optical suppression of experimental seizures in rat brain slices. ( Rode, DL; Rothman, SM; Schmidt, BF; Yang, XF, 2010) |
| "Seizures were prevented in 50% and 75% of the animals by chronic CBZ and VPC, respectively." | 1.35 | Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine. ( Nekrassov, V; Sitges, M, 2008) |
| "GYKI 52466 was effective in prolonging the latency to generalised seizures and reduction of seizure mortality." | 1.35 | Blockade of AMPA-receptors attenuates 4-aminopyridine seizures, decreases the activation of inhibitory neurons but is ineffective against seizure-related astrocytic swelling. ( Krisztin-Péva, B; Mihály, A; Weiczner, R, 2008) |
| "Rett syndrome is a neurodevelopmental disorder caused by mutations in the X-chromosomal MECP2 gene encoding for the transcriptional regulator methyl CpG binding protein 2 (MeCP2)." | 1.35 | Enhanced hypoxia susceptibility in hippocampal slices from a mouse model of rett syndrome. ( Fischer, M; Gerich, FJ; Hägele, S; Hildebrandt, B; Katschinski, D; Müller, M; Reuter, J, 2009) |
| "Within an hour of induction, seizure activity caused both a significant decrease in F-actin labeling, indicating depolymerization of F-actin, and a corresponding decrease in phosphorylated cofilin, signifying an increase in cofilin activity." | 1.34 | Hippocampal seizures cause depolymerization of filamentous actin in neurons independent of acute morphological changes. ( Erbayat-Altay, E; Hu, XY; Lee, JM; Ouyang, Y; Wong, M; Yang, XF; Zeng, LH, 2007) |
| "Inflammation was induced by injection of complete Freund's adjuvant into the rat temporomandibular joint." | 1.33 | Enhanced excitability of rat trigeminal root ganglion neurons via decrease in A-type potassium currents following temporomandibular joint inflammation. ( Ikeda, M; Kadoi, J; Matsumoto, S; Nasu, M; Takeda, M; Tanimoto, T; Yoshida, S, 2006) |
| "In addition, convulsive seizure activity was induced by systemic administration of either 4-aminopyridine (4-AP; 10 mg/kg, i." | 1.33 | Altered seizure susceptibility in mice lacking the Ca(v)2.3 E-type Ca2+ channel. ( Henry, M; Hescheler, J; Kamp, M; Krieger, A; Radhakrishnan, K; Schneider, T; Weiergräber, M, 2006) |
| "Practical devices to inhibit seizure activity may only need to induce small temperature drops, if the cooling can be applied sufficiently rapidly." | 1.33 | Termination of epileptiform activity by cooling in rat hippocampal slice epilepsy models. ( Lesser, RP; Motamedi, GK; Ortinski, PI; Rogawski, MA; Salazar, P; Smith, EL; Vicini, S; Webber, WR, 2006) |
| " With the use of a double sucrose gap-recording chamber we perform a dose-response assay to examine the effects of these compounds on axonal conduction following an in vitro stretch injury." | 1.33 | Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma. ( Borgens, RB; Byrn, SR; McBride, JM; Shi, R; Smith, DT, 2006) |
| "In cuprizone-induced demyelination, spontaneous remyelination occurs after the cessation of cuprizone diet." | 1.32 | K+ channel blockade impairs remyelination in the cuprizone model. ( Bacia, A; Soliven, B; Wollmann, R, 2004) |
| "Because focal seizures produce an increase in local cerebral metabolism and blood flow, we wanted to determine whether they might lead to changes in brain temperature." | 1.31 | Intracerebral temperature alterations associated with focal seizures. ( Chang, JH; Rothman, SM; Yang, XF, 2002) |
| "Hereditary Canine Spinal Muscular Atrophy (HCSMA) is an autosomal dominant disorder of motor neurons that shares features with human motor neuron disease." | 1.30 | Effects of 4-aminopyridine on muscle and motor unit force in canine motor neuron disease. ( Cope, TC; Cork, LC; Pinter, MJ; Waldeck, RF, 1997) |
| "With 40 rabbits, the occurrence of convulsion at this dose level was 100%." | 1.29 | [Intracerebral-ventricular injection of 4-aminopyridine induced convulsion in rabbits]. ( Cao, H; Xu, JH; Zheng, JH, 1993) |
| "Verapamil toxicity was produced in all animals following an average dose of 1." | 1.29 | Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity. ( Martin, TG; Menegazzi, JJ; Plewa, MC; Seaberg, DC; Wolfson, AB, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.20) | 18.7374 |
| 1990's | 16 (9.58) | 18.2507 |
| 2000's | 53 (31.74) | 29.6817 |
| 2010's | 91 (54.49) | 24.3611 |
| 2020's | 5 (2.99) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Fedor, FZ | 1 |
| Paraczky, C | 1 |
| Ravasz, L | 1 |
| Tóth, K | 1 |
| Borhegyi, Z | 1 |
| Somogyvári, Z | 2 |
| Juhász, G | 1 |
| Fekete, Z | 1 |
| Shi, L | 1 |
| Jia, L | 1 |
| Wang, Y | 3 |
| Xiu, M | 1 |
| Xie, J | 1 |
| Liou, JY | 2 |
| Baird-Daniel, E | 3 |
| Zhao, M | 5 |
| Daniel, A | 1 |
| Schevon, CA | 1 |
| Ma, H | 5 |
| Schwartz, TH | 5 |
| Toraman, M | 1 |
| Külekçi Öztürk, S | 1 |
| Uslu Coşkun, B | 1 |
| Güneş, P | 1 |
| Manto, KM | 1 |
| Govindappa, PK | 1 |
| Parisi, D | 1 |
| Karuman, Z | 1 |
| Martinazzi, B | 1 |
| Hegarty, JP | 1 |
| Talukder, MAH | 1 |
| Elfar, JC | 2 |
| Daniel, AGS | 1 |
| Wenzel, M | 1 |
| Li, D | 1 |
| Laffont, P | 1 |
| Yuste, R | 1 |
| Ha, Y | 1 |
| Lee, Y | 1 |
| Suh, M | 1 |
| Wynne, BM | 1 |
| Labazi, H | 1 |
| Tostes, RC | 1 |
| Webb, RC | 1 |
| Wu, X | 1 |
| Muthuchamy, M | 1 |
| Reddy, DS | 1 |
| Gu, J | 1 |
| Tian, X | 1 |
| Wang, W | 1 |
| Yang, Q | 1 |
| Lin, P | 1 |
| Ma, Y | 1 |
| Xiong, Y | 1 |
| Xu, D | 1 |
| Zhang, Y | 2 |
| Yang, Y | 1 |
| Lu, S | 1 |
| Lin, Z | 1 |
| Luo, J | 1 |
| Xiao, F | 1 |
| Wang, X | 1 |
| Nagappan, S | 1 |
| Liu, L | 1 |
| Fetcho, R | 1 |
| Nguyen, J | 2 |
| Nishimura, N | 2 |
| Radwanski, RE | 1 |
| Lieberman, S | 1 |
| Schaffer, CB | 2 |
| Islas-Espinoza, AM | 1 |
| Campos-Rodriguez, C | 1 |
| San Juan, ER | 1 |
| Derera, ID | 1 |
| Smith, KC | 1 |
| Smith, BN | 1 |
| Modrak, M | 1 |
| Sundem, L | 2 |
| Gupta, R | 1 |
| Zuscik, MJ | 1 |
| Elfar, J | 2 |
| Noble, M | 2 |
| Tseng, KC | 2 |
| Li, H | 2 |
| Slezia, A | 1 |
| Proctor, CM | 1 |
| Kaszas, A | 1 |
| Malliaras, GG | 1 |
| Williamson, A | 1 |
| Luft, JG | 1 |
| Steffens, L | 1 |
| Morás, AM | 1 |
| da Rosa, MS | 1 |
| Leipnitz, G | 1 |
| Regner, GG | 1 |
| Pflüger, PF | 1 |
| Gonçalves, D | 1 |
| Moura, DJ | 1 |
| Pereira, P | 1 |
| Honsa, P | 1 |
| Pivonkova, H | 1 |
| Anderova, M | 1 |
| Tsytsarev, V | 1 |
| Rao, B | 1 |
| Maslov, KI | 1 |
| Li, L | 1 |
| Wang, LV | 1 |
| Tang, Y | 2 |
| Durand, DM | 3 |
| Iaci, JF | 1 |
| Parry, TJ | 1 |
| Huang, Z | 1 |
| Finklestein, SP | 1 |
| Ren, J | 1 |
| Barrile, DK | 1 |
| Davenport, MD | 1 |
| Wu, R | 1 |
| Blight, AR | 2 |
| Caggiano, AO | 1 |
| Liautard, C | 1 |
| Scalmani, P | 1 |
| Carriero, G | 1 |
| de Curtis, M | 2 |
| Franceschetti, S | 1 |
| Mantegazza, M | 1 |
| Deuis, JR | 1 |
| Zimmermann, K | 1 |
| Romanovsky, AA | 1 |
| Possani, LD | 1 |
| Cabot, PJ | 1 |
| Lewis, RJ | 1 |
| Vetter, I | 1 |
| Peng, BW | 1 |
| Justice, JA | 1 |
| He, XH | 1 |
| Sanchez, RM | 1 |
| Gonzalez-Reyes, LE | 1 |
| Ladas, TP | 1 |
| Chiang, CC | 2 |
| Toprani, S | 1 |
| Vrabec, T | 1 |
| Abbasi, S | 1 |
| Abbasi, A | 1 |
| Sarbaz, Y | 1 |
| Luo, Y | 1 |
| Wu, PF | 1 |
| Zhou, J | 1 |
| Xiao, W | 1 |
| He, JG | 1 |
| Guan, XL | 1 |
| Zhang, JT | 1 |
| Hu, ZL | 1 |
| Wang, F | 1 |
| Chen, JG | 1 |
| Wijayatunge, R | 1 |
| Chen, LF | 1 |
| Cha, YM | 1 |
| Zannas, AS | 1 |
| Frank, CL | 1 |
| West, AE | 1 |
| Harris, S | 1 |
| Boorman, L | 1 |
| Bruyns-Haylett, M | 1 |
| Kennerley, A | 1 |
| Overton, PG | 1 |
| Berwick, J | 1 |
| Calvet, CM | 1 |
| Vieira, DF | 1 |
| Choi, JY | 1 |
| Kellar, D | 1 |
| Cameron, MD | 1 |
| Siqueira-Neto, JL | 1 |
| Gut, J | 1 |
| Johnston, JB | 1 |
| Lin, L | 1 |
| Khan, S | 1 |
| McKerrow, JH | 1 |
| Roush, WR | 1 |
| Podust, LM | 1 |
| Beck, R | 1 |
| Günther, L | 1 |
| Xiong, G | 1 |
| Potschka, H | 1 |
| Böning, G | 1 |
| Bartenstein, P | 1 |
| Brandt, T | 2 |
| Jahn, K | 1 |
| Dieterich, M | 1 |
| Strupp, M | 3 |
| la Fougère, C | 1 |
| Zwergal, A | 2 |
| Hamidi, S | 4 |
| Lévesque, M | 5 |
| Avoli, M | 18 |
| Siah, BH | 1 |
| Ju, MS | 1 |
| Lin, CC | 1 |
| Dabertrand, F | 1 |
| Krøigaard, C | 1 |
| Bonev, AD | 1 |
| Cognat, E | 1 |
| Dalsgaard, T | 1 |
| Domenga-Denier, V | 1 |
| Hill-Eubanks, DC | 1 |
| Brayden, JE | 1 |
| Joutel, A | 1 |
| Nelson, MT | 1 |
| Salami, P | 2 |
| Gotman, J | 2 |
| Chang, WP | 2 |
| Lu, HC | 1 |
| Shyu, BC | 2 |
| Goddeyne, C | 1 |
| Nichols, J | 1 |
| Wu, C | 1 |
| Anderson, T | 1 |
| Uva, L | 1 |
| Breschi, GL | 1 |
| Gnatkovsky, V | 1 |
| Taverna, S | 1 |
| Cramer, SW | 1 |
| Popa, LS | 1 |
| Carter, RE | 1 |
| Chen, G | 1 |
| Ebner, TJ | 1 |
| Wu, KW | 1 |
| Yang, P | 1 |
| Li, SS | 1 |
| Liu, CW | 1 |
| Sun, FY | 1 |
| Kano, T | 1 |
| Inaba, Y | 2 |
| D'Antuono, M | 8 |
| Biagini, G | 6 |
| Hongo, Y | 1 |
| Takasu, K | 1 |
| Ikegaya, Y | 1 |
| Hasegawa, M | 1 |
| Sakaguchi, G | 1 |
| Ogawa, K | 1 |
| Tao, AF | 1 |
| Xu, ZH | 1 |
| Chen, B | 1 |
| Wu, XH | 1 |
| Zhang, J | 1 |
| Tang, YS | 1 |
| Xu, CL | 1 |
| Zhao, HW | 1 |
| Hu, WW | 1 |
| Shi, LY | 1 |
| Zhang, SH | 1 |
| Chen, Z | 1 |
| Salam, MT | 1 |
| Kassiri, H | 1 |
| Genov, R | 1 |
| Perez Velazquez, JL | 1 |
| Chang, CY | 1 |
| Lin, TY | 2 |
| Lu, CW | 2 |
| Huang, SK | 2 |
| Wang, YC | 1 |
| Chou, SS | 2 |
| Wang, SJ | 2 |
| Herrington, R | 1 |
| Serafini, R | 1 |
| Dettloff, S | 1 |
| Loeb, JA | 1 |
| Haghdoost-Yazdi, H | 2 |
| Piri, H | 1 |
| Faraji, A | 2 |
| Fraidouni, N | 2 |
| Dargahi, T | 1 |
| Mahmudi, M | 1 |
| Alipour Heidari, M | 1 |
| Bellou, A | 1 |
| Al-Hammadi, S | 1 |
| Aburawi, EH | 1 |
| Dhanasekaran, S | 1 |
| Nemmar, A | 1 |
| Oulhaj, A | 1 |
| Shafiuallah, M | 1 |
| Zerrouki, M | 1 |
| Yasin, J | 1 |
| Bellou, L | 1 |
| Alper, SL | 1 |
| Bellou, S | 1 |
| Kazzam, E | 1 |
| Jayabal, S | 1 |
| Chang, HH | 1 |
| Cullen, KE | 1 |
| Watt, AJ | 1 |
| Vazana, U | 1 |
| Veksler, R | 1 |
| Pell, GS | 1 |
| Prager, O | 1 |
| Fassler, M | 1 |
| Chassidim, Y | 1 |
| Roth, Y | 1 |
| Shahar, H | 1 |
| Zangen, A | 1 |
| Raccah, R | 1 |
| Onesti, E | 1 |
| Ceccanti, M | 1 |
| Colonnese, C | 1 |
| Santoro, A | 1 |
| Salvati, M | 1 |
| D'Elia, A | 1 |
| Nucciarelli, V | 1 |
| Inghilleri, M | 1 |
| Friedman, A | 1 |
| Assaf, F | 1 |
| Schiller, Y | 1 |
| Clark, A | 1 |
| Zuscik, M | 1 |
| Shiha, AA | 1 |
| de la Rosa, RF | 1 |
| Delgado, M | 1 |
| Pozo, MA | 3 |
| García-García, L | 1 |
| Tuncer, S | 1 |
| Dalkilic, N | 1 |
| Burat, I | 1 |
| Sanya, EO | 1 |
| Soladoye, AO | 1 |
| Desalu, OO | 1 |
| Kolo, PM | 1 |
| Olatunji, LA | 1 |
| Olarinoye, JK | 1 |
| Moriguchi, K | 1 |
| Miyamoto, K | 1 |
| Kusunoki, S | 1 |
| Szakács, R | 1 |
| Xue, W | 1 |
| Zhang, M | 1 |
| Li, J | 1 |
| Wu, D | 1 |
| Niu, L | 1 |
| Liang, Y | 1 |
| Ayala, GX | 2 |
| Tapia, R | 4 |
| Nekrassov, V | 2 |
| Sitges, M | 2 |
| Su, T | 1 |
| Cong, WD | 1 |
| Long, YS | 1 |
| Luo, AH | 1 |
| Sun, WW | 1 |
| Deng, WY | 1 |
| Liao, WP | 1 |
| Fischer, M | 1 |
| Reuter, J | 1 |
| Gerich, FJ | 1 |
| Hildebrandt, B | 1 |
| Hägele, S | 1 |
| Katschinski, D | 1 |
| Müller, M | 1 |
| Bertazzoni, G | 1 |
| Világi, I | 2 |
| Dobó, E | 1 |
| Borbély, S | 2 |
| Czégé, D | 1 |
| Molnár, E | 1 |
| Mihály, A | 2 |
| Yang, XF | 3 |
| Schmidt, BF | 1 |
| Rode, DL | 1 |
| Rothman, SM | 2 |
| Köhling, R | 2 |
| Ricalzone, S | 1 |
| Pineau, J | 2 |
| Guez, A | 1 |
| Vincent, R | 1 |
| Panuccio, G | 2 |
| Hill, AJ | 2 |
| Jones, NA | 2 |
| Williams, CM | 2 |
| Stephens, GJ | 2 |
| Whalley, BJ | 2 |
| Smith, I | 1 |
| Bevan, SA | 1 |
| Govek, SP | 1 |
| Oshiro, G | 1 |
| Anzola, JV | 1 |
| Beauregard, C | 1 |
| Chen, J | 1 |
| Coyle, AR | 1 |
| Gamache, DA | 1 |
| Hellberg, MR | 1 |
| Hsien, JN | 1 |
| Lerch, JM | 1 |
| Liao, JC | 1 |
| Malecha, JW | 1 |
| Staszewski, LM | 1 |
| Thomas, DJ | 1 |
| Yanni, JM | 1 |
| Noble, SA | 1 |
| Shiau, AK | 1 |
| de Guzman, P | 1 |
| De Lannoy, L | 1 |
| Alviña, K | 1 |
| Khodakhah, K | 1 |
| Boido, D | 1 |
| Farisello, P | 1 |
| Cesca, F | 1 |
| Ferrea, E | 1 |
| Valtorta, F | 1 |
| Benfenati, F | 1 |
| Baldelli, P | 1 |
| Wilhelm, EA | 1 |
| Jesse, CR | 1 |
| Roman, SS | 1 |
| Bortolatto, CF | 1 |
| Nogueira, CW | 1 |
| Juge, N | 1 |
| Gray, JA | 1 |
| Omote, H | 1 |
| Miyaji, T | 1 |
| Inoue, T | 1 |
| Hara, C | 1 |
| Uneyama, H | 1 |
| Edwards, RH | 1 |
| Nicoll, RA | 1 |
| Moriyama, Y | 1 |
| Gonzalez-Sulser, A | 1 |
| Wang, J | 1 |
| Motamedi, GK | 2 |
| Vicini, S | 2 |
| Dzakpasu, R | 1 |
| Sleigh, JN | 1 |
| Buckingham, SD | 2 |
| Esmaeili, B | 1 |
| Viswanathan, M | 1 |
| Cuppen, E | 1 |
| Westlund, BM | 1 |
| Sattelle, DB | 2 |
| Jones, AK | 1 |
| Rayes, D | 1 |
| Al-Diwani, A | 1 |
| Maynard, TP | 1 |
| Jones, R | 1 |
| Hernando, G | 1 |
| Bouzat, C | 1 |
| Berwick, ZC | 1 |
| Payne, GA | 1 |
| Lynch, B | 1 |
| Dick, GM | 1 |
| Sturek, M | 1 |
| Tune, JD | 1 |
| Flynn, JM | 1 |
| Choi, SW | 1 |
| Day, NU | 1 |
| Gerencser, AA | 1 |
| Hubbard, A | 1 |
| Melov, S | 1 |
| Streit, AK | 1 |
| Derst, C | 2 |
| Wegner, S | 1 |
| Heinemann, U | 3 |
| Zahn, RK | 2 |
| Decher, N | 1 |
| Vincent, RD | 1 |
| Courville, A | 1 |
| Movahedi, M | 1 |
| Hadibeygi, E | 1 |
| Vaezi, F | 1 |
| Kuo, YC | 1 |
| Chou, SH | 1 |
| Tzeng, WF | 1 |
| Leu, CY | 1 |
| Huang, RF | 1 |
| Liew, YF | 1 |
| Glasauer, S | 1 |
| Rössert, C | 1 |
| Wu, JS | 1 |
| Lee, CM | 1 |
| Vogt, BA | 1 |
| Duan, KZ | 1 |
| Xu, Q | 1 |
| Zhang, XM | 1 |
| Zhao, ZQ | 1 |
| Mei, YA | 1 |
| Zhang, YQ | 1 |
| Bussek, A | 1 |
| Schmidt, M | 1 |
| Bauriedl, J | 1 |
| Ravens, U | 1 |
| Wettwer, E | 1 |
| Lohmann, H | 1 |
| Vera, G | 1 |
| Ellis, LD | 1 |
| Seibert, J | 1 |
| Soanes, KH | 1 |
| Mori, S | 1 |
| Kishi, M | 1 |
| Kubo, S | 1 |
| Akiyoshi, T | 1 |
| Yamada, S | 1 |
| Miyazaki, T | 1 |
| Konishi, T | 1 |
| Maruyama, N | 1 |
| Shigemoto, K | 1 |
| Koide, M | 1 |
| Wellman, GC | 1 |
| Alvarez, P | 1 |
| Chen, X | 1 |
| Hendrich, J | 1 |
| Irwin, JC | 1 |
| Green, PG | 1 |
| Giudice, LC | 1 |
| Levine, JD | 1 |
| Butti, E | 1 |
| Bacigaluppi, M | 1 |
| Rossi, S | 1 |
| Cambiaghi, M | 1 |
| Bari, M | 1 |
| Cebrian Silla, A | 1 |
| Brambilla, E | 1 |
| Musella, A | 1 |
| De Ceglia, R | 1 |
| Teneud, L | 1 |
| De Chiara, V | 1 |
| D'Adamo, P | 1 |
| Garcia-Verdugo, JM | 1 |
| Comi, G | 1 |
| Muzio, L | 1 |
| Quattrini, A | 1 |
| Leocani, L | 1 |
| Maccarrone, M | 1 |
| Centonze, D | 1 |
| Martino, G | 1 |
| Aldana, BI | 1 |
| Gómez, CD | 1 |
| McLeod, F | 1 |
| Ganley, R | 1 |
| Williams, L | 1 |
| Selfridge, J | 1 |
| Bird, A | 1 |
| Cobb, SR | 1 |
| van Lunteren, E | 2 |
| Moyer, M | 2 |
| Smyth, MD | 1 |
| Barbaro, NM | 1 |
| Baraban, SC | 2 |
| Olschewski, A | 1 |
| Hong, Z | 1 |
| Linden, BC | 1 |
| Porter, VA | 1 |
| Weir, EK | 1 |
| Cornfield, DN | 1 |
| Chang, JH | 1 |
| D'Arcangelo, G | 4 |
| Warren, R | 1 |
| Tancredi, V | 4 |
| Cuadrado, A | 1 |
| Amat, G | 1 |
| Armijo, JA | 1 |
| Gajda, Z | 2 |
| Gyengési, E | 2 |
| Hermesz, E | 2 |
| Ali, KS | 1 |
| Szente, M | 2 |
| Martín, ED | 2 |
| Niittykoski, M | 1 |
| Nissinen, J | 1 |
| Penttonen, M | 1 |
| Pitkänen, A | 1 |
| Ishizaki, T | 1 |
| Sakai, A | 1 |
| Koizumi, T | 1 |
| Ruan, Z | 1 |
| Wang, ZG | 1 |
| Harrison, PK | 1 |
| Tattersall, JE | 1 |
| Clement, RA | 1 |
| Nerbonne, JM | 1 |
| Bacia, A | 1 |
| Wollmann, R | 1 |
| Soliven, B | 1 |
| Brown, JT | 1 |
| Richardson, JC | 1 |
| Collingridge, GL | 1 |
| Randall, AD | 1 |
| Davies, CH | 1 |
| Weisz, CJ | 1 |
| Raike, RS | 1 |
| Soria-Jasso, LE | 1 |
| Hess, EJ | 1 |
| Kaminski, RM | 1 |
| Marini, H | 1 |
| Kim, WJ | 1 |
| Rogawski, MA | 3 |
| Smith, DT | 2 |
| Shi, R | 3 |
| Borgens, RB | 2 |
| McBride, JM | 2 |
| Jackson, K | 1 |
| Byrn, SR | 2 |
| Ceña, V | 1 |
| Belugin, S | 1 |
| Mifflin, S | 1 |
| Tovar-y-Romo, LB | 1 |
| Takeda, M | 1 |
| Tanimoto, T | 1 |
| Ikeda, M | 1 |
| Nasu, M | 1 |
| Kadoi, J | 1 |
| Yoshida, S | 1 |
| Matsumoto, S | 1 |
| Gigout, S | 1 |
| Louvel, J | 1 |
| Pumain, R | 1 |
| Mert, T | 1 |
| Gunay, I | 1 |
| Polat, S | 1 |
| Halasy, K | 1 |
| Détári, L | 1 |
| Weiergräber, M | 1 |
| Henry, M | 1 |
| Krieger, A | 1 |
| Kamp, M | 1 |
| Radhakrishnan, K | 1 |
| Hescheler, J | 1 |
| Schneider, T | 1 |
| Salazar, P | 1 |
| Smith, EL | 1 |
| Lesser, RP | 1 |
| Webber, WR | 1 |
| Ortinski, PI | 1 |
| Szupera, Z | 1 |
| Fike, CD | 1 |
| Kaplowitz, MR | 1 |
| Madden, JA | 1 |
| Ouyang, Y | 1 |
| Hu, XY | 1 |
| Erbayat-Altay, E | 1 |
| Zeng, LH | 1 |
| Lee, JM | 1 |
| Wong, M | 1 |
| Tolner, EA | 1 |
| Gruber, C | 1 |
| Veh, RW | 1 |
| Morales-Villagrán, A | 1 |
| Medina-Ceja, L | 1 |
| López-Pérez, SJ | 1 |
| Weiczner, R | 1 |
| Krisztin-Péva, B | 1 |
| Fehlings, MG | 2 |
| Nashmi, R | 2 |
| Haghighi, SS | 1 |
| Pugh, SL | 1 |
| Perez-Espejo, MA | 1 |
| Oro, JJ | 1 |
| Yamaguchi, S | 1 |
| Donevan, SD | 1 |
| Xu, JH | 2 |
| Cao, H | 1 |
| Zheng, JH | 1 |
| Plewa, MC | 1 |
| Martin, TG | 1 |
| Menegazzi, JJ | 1 |
| Seaberg, DC | 1 |
| Wolfson, AB | 1 |
| Barbarosie, M | 2 |
| Lücke, A | 1 |
| Nagao, T | 1 |
| Lopantsev, V | 1 |
| Wananukul, W | 1 |
| Keyler, DE | 1 |
| Pentel, PR | 1 |
| Pinter, MJ | 1 |
| Waldeck, RF | 1 |
| Cope, TC | 1 |
| Cork, LC | 1 |
| Chang, FC | 1 |
| Spriggs, DL | 1 |
| Benton, BJ | 1 |
| Keller, SA | 1 |
| Capacio, BR | 1 |
| He, YX | 1 |
| Shu, ST | 1 |
| Wang, LM | 1 |
| Shipsey, SJ | 1 |
| Bryant, SM | 1 |
| Hart, G | 1 |
| Onoue, H | 1 |
| Katusic, ZS | 1 |
| Buchheim, K | 1 |
| Schuchmann, S | 1 |
| Siegmund, H | 1 |
| Weissinger, F | 1 |
| Meierkord, H | 1 |
| Koyuncuoğlu, H | 1 |
| Nurten, A | 1 |
| Enginar, N | 1 |
| Ozerman, B | 1 |
| Kara , I | 1 |
| Castro, PA | 1 |
| Cooper, EC | 1 |
| Lowenstein, DH | 1 |
| Benini, R | 1 |
| Pryor, JD | 1 |
| Zona, C | 1 |
| Longone, P | 1 |
| Manfredi, M | 1 |
| Gwilt, M | 1 |
| Henderson, CG | 1 |
| Orme, J | 1 |
| Rourke, JD | 1 |
| Kamijo, T | 1 |
| Tomaru, T | 1 |
| Miwa, A | 1 |
| Nakamura, F | 1 |
| Kido, H | 1 |
| Sugimoto, T | 1 |
| Uchida, Y | 1 |
| Nockels, R | 1 |
| Young, W | 1 |
| Haroutunian, V | 1 |
| Kanof, PD | 1 |
| Tsuboyama, GK | 1 |
| Campbell, GA | 1 |
| Davis, KL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke[NCT01605825] | Phase 2 | 83 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Randomized, Double Blind, Placebo Controlled, Parallel Design Phase II b Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies[NCT04406948] | Phase 2 | 103 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| Rett Syndrome, MECP2 Duplication, and Rett-Related Disorders Consortium, Rare Disease Clinical Research Network: Neurophysiologic Correlates[NCT03077308] | 185 participants (Actual) | Observational | 2017-01-02 | Completed | |||
| Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A TEAE is defined as any adverse event with date of onset (or worsening) on or after the start-date of double-blind treatment through 7 days after the last dose of double-blind treatment.~The severity categories of mild, moderate or severe, are defined below:~Mild is defined as causing no limitation of usual activities~Moderate is defined as causing some limitation of usual activities~Severe is defined as causing inability to carry out usual activities" (NCT01605825)
Timeframe: up to 36 days
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Subjects with any TEAEs | TEAEs Possibly Related to study drug | TEAEs Maximum Severity - Mild | TEAEs Maximum Severity - Moderate | TEAEs Maximum Severity - Severe | TEAEs leading to withdrawal of study drug | TEAEs Serious | Subjects who died | |
| Dalfampridine-ER | 42 | 24 | 29 | 10 | 3 | 5 | 2 | 0 |
| Placebo | 30 | 16 | 16 | 13 | 1 | 1 | 2 | 0 |
4 reviews available for 4-aminopyridine and Disease Models, Animal
| Article | Year |
|---|---|
Studying cardiac arrhythmias in the mouse--a reasonable model for probing mechanisms?
Topics: 4-Aminopyridine; Action Potentials; Animals; Arrhythmias, Cardiac; Disease Models, Animal; ERG1 Pota | 2004 |
Episodic ataxia type 2.
Topics: 4-Aminopyridine; Acetazolamide; Animals; Calcium Channels; Carbonic Anhydrase Inhibitors; Cerebellar | 2007 |
Do interictal discharges promote or control seizures? Experimental evidence from an in vitro model of epileptiform discharge.
Topics: 4-Aminopyridine; Animals; Dentate Gyrus; Disease Models, Animal; Electric Stimulation; Electroenceph | 2001 |
Pharmacologic strategies in the treatment of experimental spinal cord injury.
Topics: 4-Aminopyridine; Animals; Baclofen; Disease Models, Animal; Gangliosides; Humans; Lipid Peroxidation | 1992 |
1 trial available for 4-aminopyridine and Disease Models, Animal
| Article | Year |
|---|---|
Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.
Topics: 4-Aminopyridine; Animals; Cross-Over Studies; Disease Models, Animal; Dose-Response Relationship, Dr | 2013 |
162 other studies available for 4-aminopyridine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Electrophysiological and behavioral properties of 4-aminopyridine-induced epileptic activity in mice.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Electrophysiological Phenomena; Epilepsy; Mice; Po | 2020 |
4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 4-Aminopyridine; Animals; Disease Models, Animal; Dopa | 2023 |
Burst suppression uncovers rapid widespread alterations in network excitability caused by an acute seizure focus.
Topics: 4-Aminopyridine; Animals; Brain; Disease Models, Animal; Electroencephalography; Isoflurane; Male; N | 2019 |
The effects of 4-aminopyridine and methylprednisolone on recovery of the facial nerve crush injury.
Topics: 4-Aminopyridine; Animals; Crush Injuries; Disease Models, Animal; Facial Nerve; Facial Nerve Injurie | 2021 |
(4-Aminopyridine)-PLGA-PEG as a Novel Thermosensitive and Locally Injectable Treatment for Acute Peripheral Nerve Injury.
Topics: 4-Aminopyridine; Acute Disease; Animals; Biocompatible Materials; Disease Models, Animal; Male; Mate | 2021 |
Glial Calcium Waves are Triggered by Seizure Activity and Not Essential for Initiating Ictal Onset or Neurovascular Coupling.
Topics: 4-Aminopyridine; Animals; Brain Mapping; Calcium; Calcium Signaling; Carbenoxolone; Diagnostic Imagi | 2017 |
Insertable NO/CO Microsensors Recording Gaseous Vasomodulators Reflecting Differential Neuronal Activation Level with Respect to Seizure Focus.
Topics: 4-Aminopyridine; Animals; Biosensing Techniques; Brain; Brain Chemistry; Carbon Monoxide; Dendrites; | 2017 |
Nitroxyl Anion Mediates Relaxation in Mesenteric Arteries from Angiotensin II Hypertensive Mice.
Topics: 4-Aminopyridine; Acetylcholine; Angiotensin II; Animals; Disease Models, Animal; Hypertension; Male; | 2017 |
Atomic force microscopy investigations of fibronectin and α5β1-integrin signaling in neuroplasticity and seizure susceptibility in experimental epilepsy.
Topics: 4-Aminopyridine; Action Potentials; Animals; Disease Models, Animal; Epilepsy; Excitatory Amino Acid | 2017 |
Inhibition of Cgkii Suppresses Seizure Activity and Hippocampal Excitation by Regulating the Postsynaptic Delivery of Glua1.
Topics: 4-Aminopyridine; Adolescent; Adult; Animals; Brain; Carbazoles; Child; Cyclic GMP; Cyclic GMP-Depend | 2018 |
In Vivo Femtosecond Laser Subsurface Cortical Microtransections Attenuate Acute Rat Focal Seizures.
Topics: 4-Aminopyridine; Animals; Cerebral Cortex; Disease Models, Animal; Electrophysiological Phenomena; F | 2019 |
Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice.
Topics: 4-Aminopyridine; Acute Disease; Animals; Anticonvulsants; Disease Models, Animal; Drug Therapy, Comb | 2018 |
Altered A-type potassium channel function in the nucleus tractus solitarii in acquired temporal lobe epilepsy.
Topics: 4-Aminopyridine; Action Potentials; Animals; Brugada Syndrome; Disease Models, Animal; Epilepsy, Tem | 2019 |
Pharmacological Attenuation of Electrical Effects in a Model of Compression Neuropathy.
Topics: 4-Aminopyridine; Animals; Decompression, Surgical; Disease Models, Animal; Epoetin Alfa; Hematinics; | 2019 |
4-Aminopyridine as a Single Agent Diagnostic and Treatment for Severe Nerve Crush Injury.
Topics: 4-Aminopyridine; Animals; Crush Injuries; Disease Models, Animal; Electron Microscope Tomography; Mi | 2019 |
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice.
Topics: 4-Aminopyridine; Animals; Brain; Craniotomy; Disease Models, Animal; Electrophoresis; Epilepsy; gamm | 2019 |
Rosmarinic acid improves oxidative stress parameters and mitochondrial respiratory chain activity following 4-aminopyridine and picrotoxin-induced seizure in mice.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Antioxidants; Behavior, Animal; Cinnamates; Depsides; Dis | 2019 |
Focal cerebral ischemia induces the neurogenic potential of mouse Dach1-expressing cells in the dorsal part of the lateral ventricles.
Topics: 4-Aminopyridine; Adult Stem Cells; Animals; Cell Count; Cell Differentiation; Disease Models, Animal | 2013 |
Photoacoustic and optical coherence tomography of epilepsy with high temporal and spatial resolution and dual optical contrasts.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Epilepsy; Mice; Photoacoustic Techniques; Potassiu | 2013 |
A novel electrical stimulation paradigm for the suppression of epileptiform activity in an in vivo model of mesial temporal lobe status epilepticus.
Topics: 4-Aminopyridine; Animals; Biophysics; Disease Models, Animal; Electric Stimulation; Epilepsy, Tempor | 2012 |
Hippocampal hyperexcitability and specific epileptiform activity in a mouse model of Dravet syndrome.
Topics: 4-Aminopyridine; Age Factors; Animals; Animals, Newborn; Bicuculline; Cerebral Cortex; Disease Model | 2013 |
An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways.
Topics: 4-Aminopyridine; Analysis of Variance; Animals; Antineoplastic Agents; Cold Temperature; Disease Mod | 2013 |
Decreased A-currents in hippocampal dentate granule cells after seizure-inducing hypoxia in the immature rat.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Biophysics; Disease Models, Animal; E | 2013 |
TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Capsaicin; Convulsants; Disease Models, Animal; Epilepsy; | 2013 |
Mechanism of highly synchronized bilateral hippocampal activity.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Disease Models, Animal; Electric Stim | 2014 |
Introducing treatment strategy for cerebellar ataxia in mutant med mice: combination of acetazolamide and 4-aminopyridine.
Topics: 4-Aminopyridine; Acetazolamide; Action Potentials; Animals; Cerebellar Ataxia; Disease Models, Anima | 2014 |
Aggravation of seizure-like events by hydrogen sulfide: involvement of multiple targets that control neuronal excitability.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Entorhinal Cortex; Hydrogen Sulfide; Magnesium Def | 2014 |
The histone lysine demethylase Kdm6b is required for activity-dependent preconditioning of hippocampal neuronal survival.
Topics: 4-Aminopyridine; Animals; Astrocytes; Bicuculline; Cell Survival; Cells, Cultured; Disease Models, A | 2014 |
Contralateral dissociation between neural activity and cerebral blood volume during recurrent acute focal neocortical seizures.
Topics: 4-Aminopyridine; Animals; Brain Mapping; Cerebrovascular Circulation; Disease Models, Animal; Electr | 2014 |
4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.
Topics: 14-alpha Demethylase Inhibitors; 4-Aminopyridine; Administration, Oral; Animals; Biological Availabi | 2014 |
The mixed blessing of treating symptoms in acute vestibular failure--evidence from a 4-aminopyridine experiment.
Topics: 4-Aminopyridine; Animals; Brain; Disease Models, Animal; Drug Administration Schedule; Fluorodeoxygl | 2014 |
Epileptiform synchronization and high-frequency oscillations in brain slices comprising piriform and entorhinal cortices.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Electroencephalography Phase Synchronization; Elec | 2014 |
Suppression of acute seizures by theta burst electrical stimulation of the hippocampal commissure using a closed-loop system.
Topics: 4-Aminopyridine; Acute Disease; Animals; Disease Models, Animal; Electric Stimulation Therapy; Forni | 2014 |
Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease.
Topics: 4-Aminopyridine; Animals; Brain; Cerebrovascular Disorders; Disease Models, Animal; Heparin-binding | 2015 |
Distinct EEG seizure patterns reflect different seizure generation mechanisms.
Topics: 4-Aminopyridine; Animals; Brain; Brain Mapping; Disease Models, Animal; Electroencephalography; Male | 2015 |
Treatment with direct-current stimulation against cingulate seizure-like activity induced by 4-aminopyridine and bicuculline in an in vitro mouse model.
Topics: 4-Aminopyridine; Animals; Bicuculline; Disease Models, Animal; Electric Stimulation; Gyrus Cinguli; | 2015 |
Repetitive mild traumatic brain injury induces ventriculomegaly and cortical thinning in juvenile rats.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Body Weight; Brain Injuries; Cerebral | 2015 |
Synchronous inhibitory potentials precede seizure-like events in acute models of focal limbic seizures.
Topics: 4-Aminopyridine; Action Potentials; Animals; Bicuculline; Computer Simulation; Convulsants; Disease | 2015 |
Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.
Topics: 4-Aminopyridine; Acetazolamide; Animals; Benzeneacetamides; Calcium Channels, N-Type; Cerebral Corte | 2015 |
VEGF attenuated increase of outward delayed-rectifier potassium currents in hippocampal neurons induced by focal ischemia via PI3-K pathway.
Topics: 4-Aminopyridine; Animals; Cerebral Infarction; Disease Models, Animal; Enzyme Inhibitors; Hippocampu | 2015 |
Blockade of in vitro ictogenesis by low-frequency stimulation coincides with increased epileptiform response latency.
Topics: 4-Aminopyridine; Amygdala; Animals; Cerebral Cortex; Disease Models, Animal; Electric Stimulation; E | 2015 |
KCC2 function modulates in vitro ictogenesis.
Topics: 4-Aminopyridine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Bumetanide; Cerebral Cortex; Disease | 2015 |
Carbonic anhydrase inhibition by acetazolamide reduces in vitro epileptiform synchronization.
Topics: 4-Aminopyridine; Acetazolamide; Animals; Anticonvulsants; Carbonic Anhydrase Inhibitors; Carbonic An | 2015 |
Heterogeneous effects of antiepileptic drugs in an in vitro epilepsy model--a functional multineuron calcium imaging study.
Topics: 4-Aminopyridine; Animals; Animals, Newborn; Anticonvulsants; Bicuculline; Calcium; Convulsants; Dise | 2015 |
The Pro-inflammatory Cytokine Interleukin-1β is a Key Regulatory Factor for the Postictal Suppression in Mice.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Electroshock; Hippocampus; Humans; Interleukin 1 R | 2015 |
Rapid brief feedback intracerebral stimulation based on real-time desynchronization detection preceding seizures stops the generation of convulsive paroxysms.
Topics: 4-Aminopyridine; Animals; CA1 Region, Hippocampal; Disease Models, Animal; Electric Stimulation; Ele | 2015 |
Hesperidin inhibits glutamate release and exerts neuroprotection against excitotoxicity induced by kainic acid in the hippocampus of rats.
Topics: 4-Aminopyridine; Animals; Calcium; Disease Models, Animal; Egtazic Acid; Enzyme Inhibitors; Excitato | 2015 |
Interneurons spark seizure-like activity in the entorhinal cortex.
Topics: 4-Aminopyridine; Action Potentials; Animals; Disease Models, Animal; Entorhinal Cortex; Excitatory A | 2016 |
Neocortical slices from adult chronic epileptic rats exhibit discharges of higher voltages and broader spread.
Topics: 4-Aminopyridine; Animals; Chronic Disease; Disease Models, Animal; Electrocorticography; Epilepsy; I | 2016 |
High frequency oscillations can pinpoint seizures progressing to status epilepticus.
Topics: 4-Aminopyridine; Animals; Brain Waves; Disease Models, Animal; Disease Progression; Electroencephalo | 2016 |
Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation.
Topics: 4-Aminopyridine; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; D | 2016 |
4-Aminopyridine, A Blocker of Voltage-Dependent K+ Channels, Restores Blood Pressure and Improves Survival in the Wistar Rat Model of Anaphylactic Shock.
Topics: 4-Aminopyridine; Acidosis; Anaphylaxis; Animals; Blood Pressure; Dinoprost; Dinoprostone; Disease Mo | 2016 |
4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6.
Topics: 4-Aminopyridine; Animals; Cerebellum; Disease Models, Animal; Electrophysiology; Female; Heterozygot | 2016 |
Glutamate-Mediated Blood-Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery.
Topics: 4-Aminopyridine; Adult; Aged; Animals; Blood-Brain Barrier; Brain Neoplasms; Disease Models, Animal; | 2016 |
The antiepileptic and ictogenic effects of optogenetic neurostimulation of PV-expressing interneurons.
Topics: 4-Aminopyridine; Action Potentials; Animals; Disease Models, Animal; Electrocorticography; Epilepsy; | 2016 |
4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Mice; Neural Conduction; Neuroprotective Agents; P | 2016 |
Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats.
Topics: 4-Aminopyridine; Animals; Brain Injuries; Caspase 9; Cell Death; Convulsants; Disease Models, Animal | 2017 |
Electrophysiological alterations in diaphragm muscle caused by abdominal ischemia-reperfusion.
Topics: 4-Aminopyridine; Action Potentials; Analysis of Variance; Animals; Biophysics; Diaphragm; Disease Mo | 2017 |
Antiseizure Effects of Ketogenic Diet on Seizures Induced with Pentylenetetrazole, 4-Aminopyridine and Strychnine in Wistar Rats.
Topics: 4-Aminopyridine; Animal Nutritional Physiological Phenomena; Animals; Biomarkers; Blood Glucose; Die | 2017 |
Sinusoidal stimulation trains suppress epileptiform spikes induced by 4-AP in the rat hippocampal CA1 region in-vivo.
Topics: 4-Aminopyridine; Animals; CA1 Region, Hippocampal; Deep Brain Stimulation; Disease Models, Animal; E | 2016 |
4-Aminopyridine ameliorates experimental autoimmune neuritis in Lewis rats.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Electromyography; Evoked Potentials, Motor; Freund | 2017 |
Neuronal proto-oncogene expression in the pharmacological assessment of the synaptic mechanisms of the hippocampus in rats.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Epilepsy, Tonic-Clonic; Gene Expression Regulation | 2008 |
Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed.
Topics: 4-Aminopyridine; Acetylcholine; Administration, Oral; Animals; Aorta; Blood Glucose; Blood Pressure; | 2008 |
HSP70 expression protects against hippocampal neurodegeneration induced by endogenous glutamate in vivo.
Topics: 4-Aminopyridine; Animals; Cell Count; Disease Models, Animal; Dizocilpine Maleate; Electroencephalog | 2008 |
Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine.
Topics: 4-Aminopyridine; Acoustic Stimulation; Animals; Anticonvulsants; Auditory Threshold; Carbamazepine; | 2008 |
Altered expression of voltage-gated potassium channel 4.2 and voltage-gated potassium channel 4-interacting protein, and changes in intracellular calcium levels following lithium-pilocarpine-induced status epilepticus.
Topics: 4-Aminopyridine; Animals; Calcium; Disease Models, Animal; Extracellular Fluid; Female; Gene Express | 2008 |
Enhanced hypoxia susceptibility in hippocampal slices from a mouse model of rett syndrome.
Topics: 4-Aminopyridine; Adenosine Triphosphate; Animals; Bicuculline; Disease Models, Animal; Disease Susce | 2009 |
Diminished presynaptic GABA(B) receptor function in the neocortex of a genetic model of absence epilepsy.
Topics: 4-Aminopyridine; Animals; Baclofen; Cell Membrane; Disease Models, Animal; Dose-Response Relationshi | 2009 |
Repeated 4-aminopyridine induced seizures diminish the efficacy of glutamatergic transmission in the neocortex.
Topics: 4-Aminopyridine; Animals; Cobalt; Convulsants; Disease Models, Animal; Epilepsy; Excitatory Amino Ac | 2009 |
Optical suppression of experimental seizures in rat brain slices.
Topics: 4-Aminopyridine; Animals; Convulsants; Disease Models, Animal; Epilepsies, Partial; GABA Agents; gam | 2010 |
Antiepileptic drugs abolish ictal but not interictal epileptiform discharges in vitro.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anticonvulsants; Brain; Carbamazepine; Convulsants; Dis | 2010 |
Treating epilepsy via adaptive neurostimulation: a reinforcement learning approach.
Topics: 4-Aminopyridine; Algorithms; Animals; Biophysics; Disease Models, Animal; Electric Stimulation Thera | 2009 |
Development of multi-electrode array screening for anticonvulsants in acute rat brain slices.
Topics: 4-Aminopyridine; Animals; Animals, Newborn; Anticonvulsants; Disease Models, Animal; Drug Evaluation | 2010 |
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anticonvulsants; Cannabidiol; Disease Models, Animal; F | 2010 |
Water-soluble PDE4 inhibitors for the treatment of dry eye.
Topics: 4-Aminopyridine; Animals; Anti-Inflammatory Agents; Binding Sites; Computer Simulation; Coumarins; C | 2010 |
In vitro ictogenesis and parahippocampal networks in a rodent model of temporal lobe epilepsy.
Topics: 4-Aminopyridine; Action Potentials; Amygdala; Animals; Disease Models, Animal; Electrophysiology; Ep | 2010 |
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Behavior, Animal; Cerebellar Ataxia; | 2010 |
Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam.
Topics: 4-Aminopyridine; Aging; Analysis of Variance; Animals; Anticonvulsants; Cerebral Cortex; Disease Mod | 2010 |
Anticonvulsant effect of (E)-2-benzylidene-4-phenyl-1,3-diselenole in a pilocarpine model in mice.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Antioxidants; Brain; Disease Models, Animal; Dose-Respons | 2010 |
Metabolic control of vesicular glutamate transport and release.
Topics: 4-Aminopyridine; Acetoacetates; Animals; Astrocytes; Behavior, Animal; Cells, Cultured; Chlorides; C | 2010 |
The 4-aminopyridine in vitro epilepsy model analyzed with a perforated multi-electrode array.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bicuculline; CA3 Region, Hippocampal; Disease Models, Ani | 2011 |
A novel Caenorhabditis elegans allele, smn-1(cb131), mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds.
Topics: 4-Aminopyridine; Alleles; Amino Acid Sequence; Animals; Caenorhabditis elegans; Disease Models, Anim | 2011 |
A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor subunit UNC-63 impairs but does not abolish channel function.
Topics: 4-Aminopyridine; Amifampridine; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Ch | 2011 |
Contribution of adenosine A(2A) and A(2B) receptors to ischemic coronary dilation: role of K(V) and K(ATP) channels.
Topics: 4-Aminopyridine; Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Anima | 2010 |
Impaired spare respiratory capacity in cortical synaptosomes from Sod2 null mice.
Topics: 4-Aminopyridine; Animals; Biomimetics; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Cerebral | 2011 |
RNA editing of Kv1.1 channels may account for reduced ictogenic potential of 4-aminopyridine in chronic epileptic rats.
Topics: 4-Aminopyridine; Animals; Convulsants; Disease Models, Animal; Entorhinal Cortex; Epilepsy; Hippocam | 2011 |
A bistable computational model of recurring epileptiform activity as observed in rodent slice preparations.
Topics: 4-Aminopyridine; Action Potentials; Animals; Computer Simulation; Disease Models, Animal; Entorhinal | 2011 |
Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
Topics: 4-Aminopyridine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Drug Interactions; | 2011 |
HTDP-2, a new synthetic compound, inhibits glutamate release through reduction of voltage-dependent Ca²⁺ influx in rat cerebral cortex nerve terminals.
Topics: 4-Aminopyridine; Amino Acid Transport System X-AG; Animals; Calcium; Calcium Channel Blockers; Calci | 2011 |
Preictal and ictal neurovascular and metabolic coupling surrounding a seizure focus.
Topics: 4-Aminopyridine; Animals; Blood Volume; Cerebral Cortex; Cerebrovascular Circulation; Disease Models | 2011 |
The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus.
Topics: 4-Aminopyridine; Animals; Ataxia; Computer Simulation; Disease Models, Animal; Electrophysiological | 2011 |
Spatiotemporal organization and thalamic modulation of seizures in the mouse medial thalamic-anterior cingulate slice.
Topics: 4-Aminopyridine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Bicuculline; Biol | 2011 |
Targeting A-type K(+) channels in primary sensory neurons for bone cancer pain in a rat model.
Topics: 4-Aminopyridine; Activating Transcription Factor 3; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2012 |
Cardiac tissue slices with prolonged survival for in vitro drug safety screening.
Topics: 4-Aminopyridine; Action Potentials; Animal Testing Alternatives; Animals; Animals, Laboratory; Anti- | 2012 |
Activation of group III metabotropic glutamate receptors by endogenous glutamate protects against glutamate-mediated excitotoxicity in the hippocampus in vivo.
Topics: 4-Aminopyridine; Amino Acids; Animals; Carboxylic Acids; Chromatography, High Pressure Liquid; Disea | 2012 |
Distinct models of induced hyperactivity in zebrafish larvae.
Topics: 4-Aminopyridine; Aconitine; Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Dose-Respons | 2012 |
3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.
Topics: 4-Aminopyridine; Amifampridine; Animals; Autoantibodies; Disease Models, Animal; Female; Mice; Myast | 2012 |
SAH-induced suppression of voltage-gated K(+) (K (V)) channel currents in parenchymal arteriolar myocytes involves activation of the HB-EGF/EGFR pathway.
Topics: 4-Aminopyridine; Animals; Arterioles; Biophysical Phenomena; Biophysics; Disease Models, Animal; Dos | 2013 |
Ectopic uterine tissue as a chronic pain generator.
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Antineoplastic Agents, Hormonal; Biophys | 2012 |
Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity.
Topics: 4-Aminopyridine; Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Carbamates; Corpus Striatu | 2012 |
The antidepressant sertraline prevents the behavioral and EEG changes induced in two animal models of seizures.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Brain; Carbamazepine; Disease Models, Animal; Electroence | 2012 |
Reduced seizure threshold and altered network oscillatory properties in a mouse model of Rett syndrome.
Topics: 4-Aminopyridine; Animals; Bicuculline; Brain Waves; Disease Models, Animal; Excitatory Amino Acid Ag | 2013 |
Improvement of dy/dy dystrophic diaphragm by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Amifampridine; Animals; Diaphragm; Disease Models, Animal; Electric Stimulation; Ho | 2002 |
Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Anticonvulsants; Carbamazepine; Disea | 2002 |
Contribution of the K(Ca) channel to membrane potential and O2 sensitivity is decreased in an ovine PPHN model.
Topics: 4-Aminopyridine; Animals; Animals, Newborn; Disease Models, Animal; Female; Gestational Age; Hyperte | 2002 |
Intracerebral temperature alterations associated with focal seizures.
Topics: 4-Aminopyridine; Animals; Blood Flow Velocity; Body Temperature; Brain; Disease Models, Animal; Elec | 2002 |
Thalamocortical oscillations in a genetic model of absence seizures.
Topics: 4-Aminopyridine; Action Potentials; Animals; Biological Clocks; Cerebral Cortex; Disease Models, Ani | 2002 |
Is the interaction between felbamate and valproate against seizures induced by 4-aminopyridine and pentylenetetrazole in mice beneficial?
Topics: 4-Aminopyridine; Analysis of Variance; Animals; Brain; Chromatography, Liquid; Disease Models, Anima | 2003 |
Sternohyoid muscle fatigue properties of dy/dy dystrophic mice, an animal model of merosin-deficient congenital muscular dystrophy.
Topics: 4-Aminopyridine; Amifampridine; Animals; Disease Models, Animal; Electric Stimulation; Humans; In Vi | 2003 |
Involvement of gap junctions in the manifestation and control of the duration of seizures in rats in vivo.
Topics: 4-Aminopyridine; Animals; Carbenoxolone; Cerebral Cortex; Connexin 43; Connexins; Disease Models, An | 2003 |
Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region.
Topics: 4-Aminopyridine; Animals; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2003 |
Electrophysiologic changes in the lateral and basal amygdaloid nuclei in temporal lobe epilepsy: an in vitro study in epileptic rats.
Topics: 4-Aminopyridine; Amygdala; Animals; Disease Models, Animal; Electric Stimulation; Electroencephalogr | 2004 |
Blunted effect of the Kv channel inhibitor on pulmonary circulation in Tibetan sheep: a model for studying hypoxia and pulmonary artery pressure regulation.
Topics: 4-Aminopyridine; Altitude; Animals; Atmosphere Exposure Chambers; Disease Models, Animal; Hypoxia; M | 2004 |
Periodic orbit analysis reveals subtle effects of atropine on epileptiform activity in the guinea-pig hippocampal slice.
Topics: 4-Aminopyridine; Action Potentials; Animals; Atropine; Disease Models, Animal; Drug Interactions; El | 2004 |
K+ channel blockade impairs remyelination in the cuprizone model.
Topics: 4-Aminopyridine; Animals; Astrocytes; Chelating Agents; Corpus Callosum; Cuprizone; Demyelinating Di | 2004 |
Synaptic transmission and synchronous activity is disrupted in hippocampal slices taken from aged TAS10 mice.
Topics: 4-Aminopyridine; Action Potentials; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cort | 2005 |
Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering.
Topics: 4-Aminopyridine; Analysis of Variance; Animals; Behavior, Animal; Caffeine; Calcium Channels, N-Type | 2005 |
Anticonvulsant activity of androsterone and etiocholanolone.
Topics: 4-Aminopyridine; Androsterone; Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; D | 2005 |
Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease.
Topics: 4-Aminopyridine; Animals; Carbamates; Disease Models, Animal; Drug Design; Drug Evaluation, Preclini | 2005 |
Cholinergic modulation of status epilepticus in the rat barrel field region of primary somatosensory cortex.
Topics: 4-Aminopyridine; Acetylcholine; Animals; Disease Models, Animal; Electroencephalography; Electromyog | 2005 |
Transient voltage-dependent potassium currents are reduced in NTS neurons isolated from renal wrap hypertensive rats.
Topics: 4-Aminopyridine; Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Radiat | 2005 |
Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Carbamates; Disease Models, Animal; Dose-Respons | 2006 |
Cerebral neurons of transgenic ALS mice are vulnerable to glutamate release stimulation but not to increased extracellular glutamate due to transport blockade.
Topics: 4-Aminopyridine; Amyotrophic Lateral Sclerosis; Animals; Biological Transport; Dicarboxylic Acids; D | 2006 |
Late N-methyl-D-aspartate receptor blockade rescues hippocampal neurons from excitotoxic stress and death after 4-aminopyridine-induced epilepsy.
Topics: 4-Aminopyridine; Animals; Cell Count; Cell Death; Chelating Agents; Disease Models, Animal; Dizocilp | 2005 |
Enhanced excitability of rat trigeminal root ganglion neurons via decrease in A-type potassium currents following temporomandibular joint inflammation.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Inflammation; Male; Membrane Potentials; Neurons; | 2006 |
Effects in vitro and in vivo of a gap junction blocker on epileptiform activities in a genetic model of absence epilepsy.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Carbenoxolone; Cerebral Cortex; Disease Models, Animal; E | 2006 |
Alterations in conduction characteristics of crushed peripheral nerves.
Topics: 4-Aminopyridine; Action Potentials; Animals; Disease Models, Animal; Drug Interactions; Electric Sti | 2005 |
Laminar analysis of initiation and spread of epileptiform discharges in three in vitro models.
Topics: 4-Aminopyridine; Action Potentials; Animals; Bicuculline; Convulsants; Disease Models, Animal; Epile | 2006 |
Altered seizure susceptibility in mice lacking the Ca(v)2.3 E-type Ca2+ channel.
Topics: 4-Aminopyridine; Animals; Blotting, Western; Calcium Channels; Calcium Channels, T-Type; Disease Mod | 2006 |
Termination of epileptiform activity by cooling in rat hippocampal slice epilepsy models.
Topics: 4-Aminopyridine; Animals; Bicuculline; Cerebrospinal Fluid; Cryotherapy; Disease Models, Animal; Ele | 2006 |
The functional significance of gap junction channels in the epileptogenicity and seizure susceptibility of juvenile rats.
Topics: 4-Aminopyridine; Animals; Animals, Newborn; Carbenoxolone; Connexins; Cortical Synchronization; Dise | 2006 |
Voltage-gated K+ channels at an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets.
Topics: 4-Aminopyridine; Animals; Arterioles; Disease Models, Animal; Hypertension, Pulmonary; Hypoxia; In V | 2006 |
Neocortical hyperexcitability in a genetic model of absence seizures and its reduction by levetiracetam.
Topics: 4-Aminopyridine; Age Factors; Animals; Anticonvulsants; Disease Models, Animal; Electric Stimulation | 2006 |
Hippocampal seizures cause depolymerization of filamentous actin in neurons independent of acute morphological changes.
Topics: 4-Aminopyridine; Actin Cytoskeleton; Actin Depolymerizing Factors; Animals; Dendritic Spines; Diseas | 2007 |
Reduced ictogenic potential of 4-aminopyridine in the perirhinal and entorhinal cortex of kainate-treated chronic epileptic rats.
Topics: 4-Aminopyridine; Animals; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Elec | 2008 |
Simultaneous glutamate and EEG activity measurements during seizures in rat hippocampal region with the use of an electrochemical biosensor.
Topics: 4-Aminopyridine; Animals; Behavior, Animal; Biosensing Techniques; Disease Models, Animal; Electroch | 2008 |
Blockade of AMPA-receptors attenuates 4-aminopyridine seizures, decreases the activation of inhibitory neurons but is ineffective against seizure-related astrocytic swelling.
Topics: 4-Aminopyridine; Analysis of Variance; Animals; Astrocytes; Behavior, Animal; Benzodiazepines; Brain | 2008 |
Assessment of axonal dysfunction in an in vitro model of acute compressive injury to adult rat spinal cord axons.
Topics: 4-Aminopyridine; Animals; Axons; Disease Models, Animal; Evoked Potentials; Male; Myelin Sheath; Ner | 1995 |
Effect of 4-aminopyridine in acute spinal cord injury.
Topics: 4-Aminopyridine; Acute Disease; Animals; Disease Models, Animal; Evoked Potentials, Somatosensory; N | 1995 |
Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models.
Topics: 4-Aminopyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Age | 1993 |
[Intracerebral-ventricular injection of 4-aminopyridine induced convulsion in rabbits].
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Disease Models, Animal; Female; Haloperidol; Injections, | 1993 |
Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity.
Topics: 4-Aminopyridine; Amifampridine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; F | 1994 |
Synchronous GABA-mediated potentials and epileptiform discharges in the rat limbic system in vitro.
Topics: 4-Aminopyridine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Analgesics; Animals; Disease Models, Animal; | 1996 |
Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.
Topics: 4-Aminopyridine; Animals; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Blood Pressure; Br | 1996 |
A new model of acute compressive spinal cord injury in vitro.
Topics: 4-Aminopyridine; Action Potentials; Acute Disease; Animals; Axons; Disease Models, Animal; Electroph | 1997 |
Effects of 4-aminopyridine on muscle and motor unit force in canine motor neuron disease.
Topics: 4-Aminopyridine; Animals; Calcium; Disease Models, Animal; Dogs; Electromyography; Female; Homozygot | 1997 |
4-Aminopyridine reverses saxitoxin (STX)- and tetrodotoxin (TTX)-induced cardiorespiratory depression in chronically instrumented guinea pigs.
Topics: 4-Aminopyridine; Animals; Bradycardia; Diaphragm; Disease Models, Animal; Dose-Response Relationship | 1997 |
[An animal model for screening of antiallergic and antipruritic drugs].
Topics: 4-Aminopyridine; Animals; Anti-Allergic Agents; Antipruritics; Disease Models, Animal; Drug Evaluati | 1996 |
Effects of hypertrophy on regional action potential characteristics in the rat left ventricle: a cellular basis for T-wave inversion?
Topics: 4-Aminopyridine; Action Potentials; Animals; Cell Membrane; Chelating Agents; Disease Models, Animal | 1997 |
The effect of subarachnoid hemorrhage on mechanisms of vasodilation mediated by cyclic adenosine monophosphate.
Topics: 4-Aminopyridine; Adenylyl Cyclases; Animals; Basilar Artery; Charybdotoxin; Colforsin; Cyclic AMP; D | 1998 |
Comparison of intrinsic optical signals associated with low Mg2+-and 4-aminopyridine-induced seizure-like events reveals characteristic features in adult rat limbic system.
Topics: 4-Aminopyridine; Adult; Animals; Disease Models, Animal; Electroencephalography; Epilepsy; Humans; L | 2000 |
The effects of different 4-aminopyridine and morphine combinations on the intensity of morphine abstinence.
Topics: 4-Aminopyridine; Animals; Behavior, Animal; Calcium; Disease Models, Animal; Glutamic Acid; Male; Mo | 2001 |
Hippocampal heterotopia lack functional Kv4.2 potassium channels in the methylazoxymethanol model of cortical malformations and epilepsy.
Topics: 4-Aminopyridine; Action Potentials; Animals; Cerebral Cortex; Choristoma; Delayed Rectifier Potassiu | 2001 |
Limbic network interactions leading to hyperexcitability in a model of temporal lobe epilepsy.
Topics: 4-Aminopyridine; Animals; Disease Models, Animal; Entorhinal Cortex; Epilepsy, Temporal Lobe; Hippoc | 2002 |
Pathological changes of isolated spinal cord axons in response to mechanical stretch.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Cell Membrane; Cell Membrane Permeability; Disea | 2002 |
Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; In Vitro Techniques; La | 2002 |
Effects of drugs on ventricular fibrillation and ischaemic K+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro.
Topics: 4-Aminopyridine; Animals; Anti-Arrhythmia Agents; Benzothiazoles; Calcium Channel Blockers; Disease | 1992 |
[The vasospasmolytic effects of nicorandil, cromakalim and pinacidil on 3,4-diaminopyridine-induced phasic contractions in canine coronary arteries as an experimental vasospasm model].
Topics: 4-Aminopyridine; Amifampridine; Animals; Benzopyrans; Coronary Vasospasm; Cromakalim; Disease Models | 1992 |
Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury.
Topics: 4-Aminopyridine; Action Potentials; Aminopyridines; Animals; Cats; Disease Models, Animal; Female; N | 1989 |
Animal models of Alzheimer's disease: behavior, pharmacology, transplants.
Topics: 4-Aminopyridine; Alzheimer Disease; Aminopyridines; Animals; Behavior, Animal; Brain; Disease Models | 1986 |